← Markets

Intuitive Surgical, Inc.

ISRG · NASDAQ

Market open$351.49$-50.84 (-12.64%)

Key statistics

Previous close$402.33
Open$365.03
Day high$367.15
Day low$349.99
52-week high$603.88
52-week low$349.99
Market cap124.48B
Volume4.56M
Average volume2.60M
P/E ratio36.54
Forward P/E27.06
EPS9.62
Dividend yield0.00%

Market context

Why it moved

Intuitive Surgical shares fell sharply after the company warned that the expiration of enhanced ACA premium subsidies is dampening demand for elective robotic surgeries, causing U.S. da Vinci procedure growth to slow and disappointing Wall Street despite a strong overall Q2 earnings beat.

ZacksSimplywallReutersUsnewsFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Intuitive Surgical has tumbled over 10% — near a 52-week low — despite posting a strong Q2 earnings beat, as investors focused on a deceleration in U.S. da Vinci procedure growth. US da Vinci procedures grew just 12% in Q2, slowing from 14% in Q1, with management citing the expiration of ACA enhanced premium subsidies and GLP-1 drug adoption weighing on bariatric cases. Multiple analysts slashed price targets post-earnings — JPMorgan cut to $450, Piper Sandler to $470, Citi to $500 — though most maintained Buy/Overweight ratings, reflecting concern that even a solid beat couldn't offset the demand growth narrative shift.

-12.1815

July 17, 2026Intuitive Surgical rose 3.4% during the regular session ahead of its Q2 earnings report, but shares are plunging roughly 11% in after-hours trading despite a strong beat — Q2 EPS of $2.80 crushed the $2.51 estimate, and revenue of $2.89B topped forecasts, with da Vinci procedures up 16% and 468 systems placed. The post-earnings selloff appears driven by elevated valuation concerns, a challenging China environment with rising domestic competition and pricing pressure flagged on the call, and a guidance range for 2026 procedure growth of 13.5%–15.5% that likely disappointed investors hoping for an upward revision after the beat.

3.4347

July 16, 2026Intuitive Surgical shares rebounded, gaining ahead of its closely watched Q2 2026 earnings report scheduled for July 16, after hitting a fresh 52-week low the prior session. The recovery came despite Mizuho lowering its price target to $500 from $525 (maintaining Neutral) and Goldman Sachs reiterating a Buy on the stock, which is down roughly 28% year-to-date. Sentiment had been rattled earlier in the week by HCA Healthcare's report of declining surgical volumes — a demand signal for Intuitive's da Vinci systems — though bulls point to the company's strong recurring revenue base (86% of Q1 revenue) and a consistent track record of earnings beats averaging 16.8% over the past four quarters.

2.4954

July 15, 2026Intuitive Surgical tumbled to a fresh 52-week low as HCA Healthcare's Q2 report revealed a 2.3% decline in inpatient surgeries and a 3.4% drop in outpatient surgeries, raising alarm bells ahead of Intuitive's own earnings on July 16. The surgical volume warning hit the robotic-surgery leader directly, given its recurring revenue model depends on procedure activity, while a wave of analyst price-target cuts — from TD Cowen ($520), Baird ($525), RBC ($600), Barclays ($651), and Evercore ISI ($430) — amplified selling pressure by resetting valuation expectations even as most firms maintained bullish ratings. Stifel bucked the trend, reiterating a Buy with a $670 target following a surgeon survey. Investors are now laser-focused on Thursday's report, watching for da Vinci procedure growth against the 13.5%–15.5% annual guide and instrument revenue per procedure, as a routine beat may no longer be sufficient at a ~49x P/E premium to medtech peers.

-6.7842

July 14, 2026Intuitive Surgical closed essentially flat ahead of its highly anticipated Q2 earnings report due July 16, as multiple analysts trimmed price targets following a recent da Vinci component recall while maintaining bullish ratings — RBC cut its target to $600 (from $650), TD Cowen to $520 (from $585), and BTIG to $512 (from $574). Goldman Sachs has pushed back against the bearish narrative, arguing the stock's ~28% decline from highs is overdone, while some analysts see 35%+ upside from current levels. The broader market faced headwinds from surging oil prices amid renewed U.S.-Iran tensions.

0.0836

July 11, 2026Intuitive Surgical edged lower ahead of its Q2 earnings report scheduled for July 16, as the healthcare sector (XLV) also pulled back on the day. Investor focus is squarely on the upcoming results, with the Zacks consensus estimate pegging Q2 sales at $2.81 billion. Adding a constructive backdrop, BMO Capital initiated coverage with an Outperform rating and a $518 price target on July 9, calling ISRG a top MedTech pick — though the stock remains under pressure, down roughly 27% year-to-date and hovering near its 52-week low of $396.68 amid broader medtech valuation resets and a mixed analyst debate over whether strong da Vinci 5 demand and 17% system placement growth in Q1 can justify the current premium multiple.

-1.159

July 10, 2026Intuitive Surgical shares edged lower, underperforming amid a volatile backdrop shaped by renewed U.S.-Iran military exchanges and geopolitical risk weighing on broader markets. The session's key positive catalyst was BMO Capital Markets initiating coverage with an Outperform rating and a $518 price target — well above current levels — citing ISRG as a top MedTech pick in a beaten-down sector. This follows strong Q1 2026 fundamentals, including 17% procedure growth and 23% revenue growth, alongside growing interest in new opportunities like appendectomy expansion, even as the stock remains down roughly 24% year-to-date.

-0.8552

July 9, 2026Intuitive Surgical closed down nearly 3%, underperforming the broader healthcare sector (XLV) as a sweeping risk-off selloff gripped markets after President Trump declared the U.S.-Iran ceasefire 'over,' sending oil prices surging over 5% and stoking fresh inflation fears. Despite the macro-driven pullback, the company's fundamental story remains intact — Q1 2026 delivered 17% procedure growth and 23% revenue gains, and analysts see the appendectomy market as a new growth runway for its Da Vinci platform. Shares are recovering modestly in after-hours trading, up ~0.6%.

-2.8551

Seeking Alpha · July 17, 2026Intuitive Surgical stock falls despite Q2 beat (ISRG:NASDAQ)Barron's · July 17, 2026Why This Surgical Robot Stock Is Still a Buy During Its Worst Day in 4 YearsReuters · July 17, 2026Intuitive Surgical falls as Obamacare concerns rekindle medtech demand debateBloomberg · July 16, 2026Intuitive Surgical Drops as ACA Changes, GLP-1s Weigh on GrowthInvestor's Business Daily · July 16, 2026Robotic Surgery Giant Crashes After Guiding To Its Slowest Growth In YearsInvesting.com · July 16, 2026Earnings call transcript: Intuitive Surgical beats Q2 2026 estimates, shares fallNAI500 · July 15, 2026Intuitive Surgical’s Stock Has Fallen Over 25% This Year, but Goldman Sachs Still Recommends Investors BuyInvestor's Business Daily · July 14, 2026Why Intuitive Surgical And Its Peers Just Took A Tumble
Mt Newswire · July 17, 2026Intuitive Surgical Faces Rising Competitive Pressure, Long-Term Pricing Risks, Oppenheimer Says
Benzinga · July 17, 2026Mizuho Maintains Neutral on Intuitive Surgical, Lowers Price Target to $400
Benzinga · July 17, 2026Wells Fargo Maintains Overweight on Intuitive Surgical, Lowers Price Target to $487
Benzinga · July 17, 2026TD Cowen Maintains Buy on Intuitive Surgical, Lowers Price Target to $485
Benzinga · July 17, 2026RBC Capital Maintains Outperform on Intuitive Surgical, Lowers Price Target to $575
Benzinga · July 17, 2026Stifel Maintains Buy on Intuitive Surgical, Lowers Price Target to $550
Mt Newswire · July 17, 2026Deutsche Bank Adjusts Intuitive Surgical Price Target to $324 From $366, Maintains Sell Rating
Mt Newswire · July 17, 2026RBC Capital Adjusts Intuitive Surgical Price Target to $575 From $600, Maintains Outperform Rating

Peers

S&P 500SPX · $7,478.32-0.74%Medtronic plcMDT · $83.68+0.14%Johnson & JohnsonJNJ · $253.24+1.31%Stryker CorporationSYK · $322.89-2.51%Boston Scientific CorporationBSX · $44.18-0.99%Abbott LaboratoriesABT · $101.70+2.90%Becton, Dickinson and CompanyBDX · $159.68-0.16%Zimmer Biomet Holdings, Inc.ZBH · $92.27-1.58%Globus Medical, Inc.GMED · $78.14-3.42%Edwards Lifesciences CorporationEW · $86.15-1.93%ResMed Inc.RMD · $200.58-1.08%DexCom, Inc.DXCM · $76.49-1.91%